rs121434287 — SLC39A4 SLC39A4 zinc transporter variant

ZIP4 Pro200Leu — A Founding Mutation in Acrodermatitis Enteropathica

Every cell in your body needs zinc, yet humans have no meaningful way to store it. Every milligram must be absorbed fresh from the diet, almost entirely through the duodenum and proximal jejunum. The protein responsible for ferrying zinc from the gut lumen into intestinal cells is ZIP4¹¹ ZIP4
Zinc/Iron Regulated Transporter-related Protein 4 — encoded by SLC39A4 (solute carrier family 39 member 4) on chromosome 8q24.3, a twelve-pass transmembrane transporter that acts as the body's primary zinc gate. When ZIP4 is broken, zinc cannot cross the intestinal wall in sufficient quantities, and the consequences unfold quickly.

The c.599C>T variant (rs121434287) swaps a proline for a leucine at position 200 of the ZIP4 protein (p.Pro200Leu). It is one of the founding mutations identified in acrodermatitis enteropathica²² acrodermatitis enteropathica
AE — from Greek: acral (affecting the extremities and face), dermatitis (skin inflammation), and enteropathica (intestinal disease). First described by Brandt in 1936 and named by Danbolt and Closs in 1943 (AE), a rare autosomal recessive disorder of inherited zinc deficiency. Two copies of pathogenic SLC39A4 variants — either homozygous or compound heterozygous — lead to near-complete failure of intestinal zinc absorption, producing the clinical triad of periorificial and acral dermatitis, chronic diarrhea, and alopecia.

The Mechanism

ZIP4 is an unusual transporter: it moves zinc by coupling zinc influx to proton influx, exploiting the pH gradient at the gut lumen surface. The protein folds into an extracellular domain (ECD) containing two subdomains — the HRD domain and the PCD domain³³ PCD domain
Potentially Conserved Domain — a structural region conserved across ZIP family members — linked by a short linker region that includes Pro200.

Structural studies⁴⁴ Structural studies
Kuliyev E et al. Zinc transporter mutations linked to acrodermatitis enteropathica disrupt function and cause mistrafficking. J Biol Chem, 2021 showed that Pro200 sits in this linker region and that the P200L substitution causes ZIP4 to misfold. The mutant protein fails to traffic to the apical cell surface of enterocytes, becoming trapped in the endoplasmic reticulum with immature glycosylation. The functional result is complete abolition of zinc transport activity — not just a partial reduction. Cells expressing P200L ZIP4 take up zinc at rates indistinguishable from cells expressing no ZIP4 at all.

Functional studies⁵⁵ Functional studies
Hoch E et al. Elucidating the H+ Coupled Zn2+ Transport Mechanism of ZIP4; Implications in Acrodermatitis Enteropathica. Int J Mol Sci, 2020 confirmed that P200L disrupts the proton-coupled zinc transport mechanism specifically, with the mutant showing severely reduced capacity to couple H+ influx to Zn2+ uptake compared to wild-type ZIP4.

The Evidence

Acrodermatitis enteropathica is one of the better-characterized single-gene zinc disorders precisely because its cause was confirmed at the molecular level. SLC39A4 was identified as the AE gene in 2002, and the Pro200Leu variant is among the earliest mutations reported. A comprehensive mutation update⁶⁶ comprehensive mutation update
Schmitt S et al. An update on mutations of the SLC39A4 gene in acrodermatitis enteropathica. Hum Mutat, 2009 catalogued 44 distinct pathogenic variants, documenting the mutational spectrum across all exons and confirming that most patients carry compound heterozygous mutations rather than two copies of the same variant.

ClinVar lists this variant (VCV000003537) as Pathogenic/Likely pathogenic with criteria provided by seven independent diagnostic laboratories, with no classification conflicts. The associated condition is hereditary acrodermatitis enteropathica (OMIM 201100).

Without zinc replacement, AE follows a predictable course: infants present within weeks of weaning with periorificial dermatitis, diarrhea, failure to thrive, and alopecia. The condition can be fatal if unrecognized. With consistent zinc supplementation (5–10 mg/kg/day elemental zinc for acute disease; 1–2 mg/kg/day for maintenance), symptoms resolve rapidly and prognosis is excellent — lifelong supplementation is required, but patients can live normally.

Heterozygous Carriers

Heterozygous carriers have one functional ZIP4 allele and one P200L allele. With 50% of ZIP4 protein functioning normally, zinc absorption is maintained at sufficient levels for health under normal dietary conditions. Published case series confirm that parents of AE patients — who are obligate heterozygotes — do not develop AE. Some studies have noted that carriers may have modestly reduced zinc absorption under high-demand conditions (illness, pregnancy, poor diet), but this has not been quantified precisely and clinical AE does not occur in heterozygotes.

Practical Actions

Because AE is autosomal recessive, the practical significance of a single heterozygous P200L allele is primarily in the context of family planning and reproductive genetics. Carriers should be aware that if both parents carry a pathogenic SLC39A4 variant, each child has a 25% chance of inheriting biallelic variants and developing AE. Prenatal or preconception genetic counseling is appropriate when a carrier couple is identified.

For homozygous or compound heterozygous individuals, the clinical course depends on early identification and zinc supplementation initiation. Modern diagnostic genetic testing can confirm the diagnosis, and treatment (zinc sulfate orally) is inexpensive, highly effective, and well tolerated.

Interactions

Compound heterozygosity is the rule rather than the exception in AE. Most patients carry two different pathogenic SLC39A4 variants on their two chromosomes — for example, P200L on one chromosome and a frameshift or splice-site mutation on the other. The clinical severity is generally comparable across different compound heterozygous combinations, though some genotype-phenotype variability exists. For AE patients, the supervising clinician should characterize both SLC39A4 alleles to confirm the diagnosis and facilitate family cascade testing.